Authors
Latest:
Oncology Peer Review On-The-Go Podcast: Cervical Cancer Screenings/Survival in Those 65+ YearsJulianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.
Latest:
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in ItalyA survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Latest:
Addressing Social Norms Influencing Receipt of Aggressive End-of-Life CareAccording to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Latest:
Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLCMisako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, emphasize the importance of patient education, discussing how understanding the biological reasons behind treatments for EGFR-mutated non-small cell lung cancer and their side effects can lead to better outcomes, and highlighting the need for collaborative care and clear communication.
Latest:
Treatment Considerations for Bispecific Antibodies and Unmet Needs in MMThe expert panel overviews factors to consider with bispecific antibodies and offers closing insights on unmet needs in the multiple myeloma treatment space.
Latest:
Future of R/R MM: Emerging AgentsIn this segment, Dr Mohan asks Dr Mann about emerging investigational agents for the management of relapsed/refractory multiple myeloma (R/R MM) that show particular promise.
Latest:
Patient-Centered Approaches in EGFR-Mutated NSCLCPanelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.
Latest:
Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple MyelomaResults of the PREDATOR-MRD trial found that daratumumab could help predict MRD response for patients with multiple myeloma.
Latest:
Exploring New Possibilities in Kidney Cancer Detection and TherapyExperts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.
Latest:
3 Things You Should Know About the Multimodal Treatment of SCLCHere are 3 things you should know about the multimodal treatment of patients with SCLC.
Latest:
Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Key Highlights of the Phase 3 ASPEN TrialThe trial evaluated zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenström macroglobulinemia.
Latest:
Identifying Indications for Neoadjuvant Therapy in CholangiocarcinomaThe recent Hot Topics section focuses on survival rates for patients with cholangiocarcinoma.
Latest:
Recent Advances in the Understanding of MCL BiologyElias Campo, MD, PhD, provides insight into biological subtyping and the tumor microenvironment relating to mantle cell lymphoma.
Latest:
Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLCBenmelstobart-based regimens provide clinically meaningful PFS benefits as consolidation therapy for unresectable stage III non–small cell lung cancer.
Latest:
Elevating the Quality of Cancer Care via Cross-Department CollaborationExperts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
Latest:
Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate CancerONCOLOGY® editorial board member E. David Crawford, MD, and colleagues, propose a new model for guiding the treatment of prostate cancer that focuses on a “transitional state,” which occurs during the interval of progression to metastatic castration-resistant prostate cancer.
Latest:
Striving for Health Care Equity by Closing the Cancer Care Gap“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”
Latest:
Cross Q&A: Role of Belantamab Mafodotin in MMThe panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.
Latest:
Efficacy and Safety of Zolbetuximab in Gastric CancerZolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
